You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 128 No. 2, February 2010 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Research Letters
 •Online Features
 This Article
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (16)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •External Eye Disease
 •Ocular/ Adnexal Tumors
 •Pediatric Ophthalmology
 •Pediatrics
 •Neonatology and Infant Care
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Topical Treatment for Capillary Hemangioma of the Eyelid Using β-Blocker Solution

Suqin Guo, MD; Nina Ni, BA

Arch Ophthalmol. 2010;128(2):255-256. doi:10.1001/archophthalmol.2009.370

The prevalence of periorbital or eyelid hemangioma ranges from 1% to 3%. There are more than 1.5 million affected children in the United States.1 Amblyopia is the most common complication of capillary hemangioma of the eyelid in children, with an incidence of 60%. If it is not treated promptly, it may lead to irreversible blindness in young children.2 The treatment options include corticosteroids, interferon alfa-2a, laser therapy, embolization, immunomodulators, surgery, and systemic propranolol.1, 3-4 All therapeutic options are associated with adverse effects, some of which are serious. The treatment of a large capillary hemangioma on a child's left upper eyelid using topical β-blocker solution is reported. The hemangioma significantly improved within a few weeks of the topical treatment.

Report of a Case



A 4-month-old girl had a large capillary hemangioma on her left upper eyelid that induced blepharoptosis and covered her pupil (Figure 1). Her right eye followed and fixated well, while the left eye was slow to fixate. She was orthophoric with full duction and version in all fields of gaze. Her ocular examination showed a normal anterior segment, optic nerve, and retina in both eyes. Her cycloplegic retinoscopy results were +3.50 – 1.50 x 180° OD and +4.50 – 3.75 x 180° OS with more than 2 diopters of induced astigmatic anisometropia. The child's mother was instructed to apply timolol maleate, 0.5%, ophthalmic solution twice daily, 2 drops onto the surface of the hemangioma with a gentle spread using a finger. The child was not receiving systemic medication and was followed up by her pediatrician during the treatment period. After 5 weeks of treatment, the hemangioma was significantly reduced in size, thickness, and color, clearing the visual axis (Figure 2). Topical β-blocker treatment was discontinued at 7 weeks and repeat retinoscopy results at 11 weeks improved to +4.00 – 1.50 x 180° OS. The child has been followed up for 4 months and tolerated the topical treatment well. No local or systemic adverse effects were noted.


Figure 1
View larger version (66K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Figure 1. Before topical treatment, a large capillary hemangioma involved the child's left upper eyelid, inducing mechanical blepharoptosis and covering her left pupil.



Figure 2
View larger version (81K):
[in this window]
[in a new window]
[as a PowerPoint slide]
 
Figure 2. After a few weeks of treatment with topical β-blocker eyedrops, the hemangioma was significantly reduced in size, thickness, and color. The mechanical blepharoptosis also improved significantly, clearing the visual axis.



Comment

Capillary hemangioma is the most common benign tumor of the eyelid or orbit in children. It affects more than 2% of infants.3 Indications for treatment are amblyopia, compressive optic neuropathy, and exposure keratopathy.1, 3 All current therapeutic options can be associated with systemic adverse effects. First-line therapy includes oral or intralesional corticosteroids. The complications of corticosteroid treatment include disfiguring eyelid changes, elevated intraocular pressure, central retinal artery occlusion, hypertension, and adrenal cortical insufficiency.1, 3, 5 Surgical excision can be complicated by hemorrhage and infection. Therapy with immunomodulators has been associated with myelosuppression and hepatotoxic effects (cyclophosphamide) and neurotoxic effects (interferon alfa-2a).3

Most recently, systemic application of propranolol was reported to successfully treat severe hemangioma in infants.4 However, oral application of propranolol can cause severe systemic complications. These include bronchospasm, vasospasm, hypoglycemia, hypotension, severe bradycardia, heart blockage, and congestive heart failure.6 Our case demonstrates that the application of topical β-blocker solution produced significant reduction of a large capillary hemangioma and resulted in the clearance of the child's visual axis within a few weeks of treatment. No local or systemic adverse effects were noted.

These results suggest that topical β-blocker administration provides a safe and effective alternative to systemic use in the treatment of capillary hemangioma. Our ongoing studies include a case series on the treatment of capillary hemangioma with topical β-blocker solution and a comparison of the efficacy and adverse effects of topical vs systemic β-blocker in the treatment of capillary hemangioma of the eyelid.


AUTHOR INFORMATION

Correspondence: Dr Guo, The Institute of Ophthalmology and Visual Science, University of Medicine and Dentistry of New Jersey–New Jersey Medical School, 90 Bergen St, DOC 6100, Newark, NJ 07101 (guos1{at}umdnj.edu).

Financial Disclosure: None reported.

Author Affiliations: The Institute of Ophthalmology and Visual Science, University of Medicine and Dentistry of New Jersey–New Jersey Medical School, Newark (Dr Guo); and Yale University School of Medicine, New Haven, Connecticut (Ms Ni).


REFERENCES

1. Slaughter K, Sullivan T, Boulton J, O’Reagan P, Gole G. Early surgical intervention as definitive treatment for ocular adnexal capillary haemangioma. Clin Experiment Ophthalmol. 2003;31(5):418-423. FULL TEXT | WEB OF SCIENCE | PUBMED
2. Schwartz SR, Blei F, Ceisler E, Steele M, Furlan L, Kodsi S. Risk factors for amblyopia in children with capillary hemangiomas of the eyelids and orbit. J AAPOS. 2006;10(3):262-268. FULL TEXT | WEB OF SCIENCE | PUBMED
3. Peralta RJ, Glavas IP. Review of capillary hemangioma. EyeNet. February 2009:35-37.
4. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649-2651. FULL TEXT | WEB OF SCIENCE | PUBMED
5. Weiss AH, Kelly JP. Reappraisal of astigmatism induced by periocular capillary hemangioma and treatment with intralesional corticosteroid injection. Ophthalmology. 2008;115(2):390-397, e1. FULL TEXT | WEB OF SCIENCE | PUBMED
6. Siegfried EC, Keenan WJ, Al-Jureidini S. More on propranolol for hemangiomas of infancy. N Engl J Med. 2008;359(26):2846-2847. FULL TEXT | WEB OF SCIENCE | PUBMED


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Oral Propranolol for Treatment of Periocular Infantile Hemangiomas
Missoi et al.
Arch Ophthalmol 2011;129:899-903.
ABSTRACT | FULL TEXT  

Topical Timolol for Periocular Hemangioma: Report of Further Study
Ni et al.
Arch Ophthalmol 2011;129:377-379.
FULL TEXT  

Topical Timolol Solution for Infantile Hemangioma of the Eyelid
Journal Watch Dermatology 2010;2010:1-1.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2010 American Medical Association. All Rights Reserved.